• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcus Biosciences Inc.

    11/14/25 4:07:41 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCUS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Arcus Biosciences, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    03969F109

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03969F109


    1Names of Reporting Persons

    Point72 Asset Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,332,479.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,332,479.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,332,479.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    03969F109


    1Names of Reporting Persons

    Point72 Capital Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,332,479.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,332,479.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,332,479.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    03969F109


    1Names of Reporting Persons

    Steven A. Cohen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,332,479.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,332,479.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,332,479.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Arcus Biosciences, Inc.
    (b)Address of issuer's principal executive offices:

    3928 Point Eden Way Hayward, CA 94545
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Shares"), of Arcus Biosciences, Inc. held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to Shares held by an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Each of Cubist Systematic Strategies, LLC and Point72 Asia (Singapore) Pte. Ltd. are advisors under common control with Point72 Asset Management, and each acts as a sub-advisor with respect to a portion of the Shares reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
    (c)Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    03969F109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2025. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein.
    (b)Percent of class:

    4.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2025.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2025.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2025.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2025.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a).
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Point72 Asset Management, L.P.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:11/14/2025
     
    Point72 Capital Advisors, Inc.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:11/14/2025
     
    Steven A. Cohen
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:11/14/2025
    Get the next $RCUS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RCUS

    DatePrice TargetRatingAnalyst
    2/26/2025$18.00 → $24.00Neutral → Buy
    H.C. Wainwright
    10/21/2024$20.00Neutral
    H.C. Wainwright
    10/8/2024$29.00Overweight
    Wells Fargo
    11/18/2022$33.00Neutral
    BofA Securities
    10/11/2022$40.00Overweight
    Morgan Stanley
    11/19/2021$42.00 → $53.00Buy
    Citigroup
    11/19/2021$48.00 → $60.00Overweight
    Barclays
    11/18/2021$68.00 → $100.00Outperform
    SVB Leerink
    More analyst ratings

    $RCUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:06:05 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:05:56 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gilead Sciences, Inc. bought $14,999,996 worth of shares (1,363,636 units at $11.00), increasing direct ownership by 5% to 31,424,760 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/20/25 7:42:29 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arcus Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Arcus Biosciences from Neutral to Buy and set a new price target of $24.00 from $18.00 previously

    2/26/25 7:16:55 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Arcus Biosciences with a new price target

    H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00

    10/21/24 7:58:13 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Arcus Biosciences with a new price target

    Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00

    10/8/24 7:34:04 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcus Biosciences Inc.

    SCHEDULE 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    11/14/25 4:07:41 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Arcus Biosciences Inc.

    SCHEDULE 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    11/5/25 5:19:42 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Arcus Biosciences Inc.

    8-K - Arcus Biosciences, Inc. (0001724521) (Filer)

    11/3/25 4:17:26 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Jarrett Jennifer exercised 50,291 shares at a strike of $1.23 and sold $954,066 worth of shares (50,291 units at $18.97) (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    11/12/25 4:04:19 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Jaen Juan C. sold $87,650 worth of shares (4,314 units at $20.32) (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    11/3/25 4:46:01 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Jaen Juan C. sold $2,010,578 worth of shares (96,859 units at $20.76) (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    10/30/25 8:49:09 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $18.25 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences has granted the underwriters a 30-day option to purch

    10/30/25 11:35:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Announces Commencement of Public Offering of Common Stock

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may b

    10/30/25 4:01:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

    Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney cancer Multiple readouts from the ARC-20 study of casdatifan are expected in 2026, including additional analyses of the late-line monotherapy cohorts early in 2026, followed by more mature data from the casdatifan plus cabozantinib cohort in mid-2026 and initial data from the early-line cohorts in the second half of 2026 Domvanalimab plus zimberelimab and chemotherapy showed a median overall survival (OS) of 26.7 months in Arm A1 of the Phase 2 EDGE-Gastric study (overall

    10/28/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

    SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    11/12/24 9:50:12 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

    SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    10/17/24 11:31:06 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Financials

    Live finance-specific insights

    View All

    Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

    Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line ccRCC patients, both of which will begin shortly Arcus will host a conference call to discuss these data at 5:0

    6/1/25 10:45:00 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

    Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Additional data from the ARC-20 cohorts evaluating casdatifan monotherapy in patients who had progressed on both an anti-PD-1 and a tyrosine kinase inhibitor (TKI) therapy are expected in the fall Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in the second quarter of 2025 Arcus is well positioned

    5/6/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

    New data from the Phase 1/1b ARC-20 cohort evaluating HIF-2a inhibitor casdatifan in combination with cabozantinib in clear cell renal cell carcinoma (ccRCC) will be presented in an oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The ASCO presentation will include a more mature data cut than that described in the abstract and will include safety and initial efficacy data for the 100mg casdatifan once-daily (QD) plus 60mg cabozantinib QD cohort Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing diff

    4/23/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Leadership Updates

    Live Leadership Updates

    View All

    Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock at an exercise price per share of $12.45, which was the closing price on February 10, 2025, and restricted stock units to acquire a total of 75,193 shares of the Company's common stock. In addition to the awards to Dr. Markus, the Co

    2/11/25 4:35:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

    Dr. Markus will oversee Arcus's clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies   Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus's responsibilities will include oversight of Arcus's clinical development

    1/21/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo

    8/24/22 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care